

---

**UPDATES TO SHAREHOLDERS ON RECENT CLAIMS AGAINST OUE LIPPO  
HEALTHCARE LIMITED AND/OR ITS SUBSIDIARIES**

---

The Board of Directors (“**Board**”) of OUE Lippo Healthcare Limited (“**Company**”) refers to the Company’s announcements dated 27 January 2017, 8 February 2017, 22 February 2017, 21 September 2017, 30 October 2017 and 18 December 2017. The Board wishes to update the Company’s shareholders on the following claims:

1. In the Company’s announcement dated 21 September 2017, the Company referred to the alleged claims made by Ms Lim Beng Choo (“**Ms Lim**”) that were informed to the Company on or around 26 January 2017 and 7 April 2017. Further to the claims made by Ms Lim for her unpaid salaries as announced by the Company on 18 December 2018, the Board wishes to update shareholders that the Company has today been served with court documents by Ms Lim’s lawyers following Ms Lim’s commencement on 15 August 2018 of court proceedings against the Company for the sum of S\$90,000 being the alleged aggregate of her 3 months’ salary in lieu of notice, the sum of S\$72,000 being the alleged encashment of her unconsumed leave, and further damages to be assessed in respect of her alleged constructive dismissal by the Company.

The Company is consulting its legal advisors and will instruct them on the appropriate action to take on behalf of the Company. The Company will update shareholders as appropriate in due course.

2. In the Company’s announcement dated 30 October 2017, the Company referred to a claim brought by one Mr David Lin Kao Kun (林高坤) against the Company’s downstream subsidiaries in the People’s Republic of China (“**PRC**”), namely Shanghai Yilin Medical Management Consulting Co. Ltd (上海医霖医疗咨询管理有限公司) (“**Shanghai Yilin**”) and Wuxi Yilin Health Management Co. Ltd (无锡医霖健康管理有限公司) (“**Wuxi Yilin Health**”) (as a third party), before the Shanghai Pudong New District Courts (上海市浦东新区人民法院) (“**Pudong Court**”).

In these proceedings, Mr David Lin alleged that he had entered into an agreement with Wuxi Yilin Health on or around 5 June 2014 for Wuxi Yilin Health to hold its approximately 71% shares in Shanghai Yilin on trust for Mr David Lin, in consideration of him performing a capital injection into Shanghai Yilin. On this basis, Mr David Lin sought a court order determining that he was the owner of the 71% shares in Shanghai Yilin.

On 27 August 2018, the Company’s PRC counsel received the Pudong Court’s decision on the matter. According to the Pudong Court’s decision, Mr David Lin had filed an application to request to withdraw the case on 11 August 2018, and the Pudong Court approved Mr David Lin’s request on 21 August 2018. The Board is advised that the proceedings have thus concluded and no further action is required by the Company.

**OUE Lippo Healthcare Limited**

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

By Order of the Board

Dr Wong Weng Hong  
Chief Executive Officer and Executive Director  
3 September 2018

---

*This announcement has been prepared by the Company and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).*